Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: JNJ stock price vs L: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at L's multiple
Needs L P/E.
Implied fair value · at JNJ's multiple
Needs JNJ P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
Bear
$76.44
Base
$92.02
Bull
$112.30
LOEWS CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
JNJ vs PFE
Eli Lilly and Company
JNJ vs LLY
Abbott Laboratories
JNJ vs ABT
Amgen Inc.
JNJ vs AMGN
BERKSHIRE HATHAWAY INC
JNJ vs BRK-B
MARKEL GROUP INC.
JNJ vs MKL
CNA FINANCIAL CORP
JNJ vs CNA
AMERICAN INTERNATIONAL GROUP, INC.
JNJ vs AIG
GENERAL ELECTRIC CO
JNJ vs GE
3M CO
JNJ vs MMM
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe JNJ’s premium margins and ROIC can persist despite the weak 3/9 Piotroski signal, then hold or selectively add on pullbacks because the stock’s operational quality is better than L even though valuation screens above both L and DCF range.
JNJ trades at a meaningful premium to L on every listed valuation metric, with P/E at 23.4x versus 14.5x, P/S at 6.6x versus 1.3x, and EV/EBITDA at 16.3x versus 6.6x. The model’s implied price of $159.76 is 38.0% below the current price of $257.58, but that gap should be viewed alongside JNJ’s stronger operating profile and the fact that its price still sits within the historical band of $231.82 to $283.34.
Supporting Metrics
